Table. 2.

Table. 2.

Sub-group analysis for overall survival and disease-free survival with respect to site of disease involvement

Site of metastatic disease Overall survival (mon) Disease free survival (mon)


Median 95% CI p-value Median 95% CI p-value
N2 disease 19.000 12.4–25.6 0.001 11.000 7.4–14.6 < 0.01
Inter-aortocaval node 11.000 7.8–14.2 5.000 3.4–6.6
Peritoneal 12.000 10.3–13.7 4.000 2.5–5.5
Liver metastases 8.000 6.9–9.0 3.000 0.5–5.5
Oligo-metastases 19.000 13.3–24.7 9.000 7.0–10.9
Port site metastases 23.000 16.8–29.2 13.000 5.2–20.7

CI, confidence interval.

Ann Hepatobiliary Pancreat Surg 2023;27:180-8 https://doi.org/10.14701/ahbps.22-111
© 2023 Ann Hepatobiliary Pancreat Surg